search
Back to results

Reinforcement of Closure of Stoma Site (ROCSS)

Primary Purpose

Hernia

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Strattice™ Reconstructive Tissue Matrix
Standard Closure
Sponsored by
University of Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hernia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Require an elective closure of an ileostomy or a colostomy.
  • Able and willing to provide written informed consent.
  • Aged 18 years or over.

Exclusion Criteria:

  • Taking part in another clinical study which is related to the surgical procedure.
  • Allergic to any porcine or collagen products.
  • History of familial adenomatous polyposis, due to increased risk of desmoid tumours.
  • The surgeon determines that a mesh repair will definitely be required e.g. due to large parastomal hernia.
  • Unable or unwilling to provide written informed consent.

Sites / Locations

  • Hvidovre Hospital
  • Academisch Medisch Centrum
  • Tameside General Hospital
  • Royal United Hospital Bath
  • Heart of England NHS Foundation Trust
  • Queen Elizabeth Hospital
  • Sandwell General Hospital
  • Pilgrim Hospital
  • Bristol Royal Infirmary
  • Broomfield Hospital
  • St Peters Hospital
  • Chesterfield Royal Hospital
  • Western Sussex Hospitals NHS Foundation Trust
  • University Hospital Coventry
  • Doncaster Royal Infirmary
  • Dorset Country Hospital
  • James Paget University Hospital
  • St Marks Hospital
  • Raigmore Hospital
  • University Hospitals of Leicester NHS Trust
  • Macclesfield District General Hospital
  • Queen Elizabeth the Queen Mother Hospital
  • Norfolk & Norwich University Hospital
  • Queens Medical Centre
  • Salisbury District Hospital
  • University Hospital of North Tees
  • Royal Stoke University Hospital
  • Kings Mill Hospital
  • Manor Hospital
  • Royal Albert Edward Infirmary
  • New Cross Hosptial
  • Worcestershire Royal Hospital
  • Wythenshawe Hosptial
  • Yeovil District Hospital
  • York Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Strattice™ Reconstructive Tissue Matrix

Standard closure

Arm Description

Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).

Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures. Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon.

Outcomes

Primary Outcome Measures

Rate of clinically detectable hernias at two years post-randomisation.

Secondary Outcome Measures

Radiological hernia rate at one year post-randomisation.
An exploratory analysis will also compare radiological hernia rate at 1 year with clinical hernia rate at 2 years to assess the value of using a CT scan as an early diagnostic tool of incisional hernias.
Incidence of developing a symptomatic hernia evaluated at 12 and 24 months postrandomisation.
The clinical detection of hernias defined by palpable fascial defects, and global weaknesses around closed stoma sites without palpable fascial defects, will be recorded. Patient-reported hernia symptoms including a local lump or pain at the site of the stoma closure will also be collected.
Surgical re-intervention rates at 2 years post-randomisation.
Surgical complications, including wound infections and seroma formation, at 30 days postoperatively and at 1 year post-randomisation.
Quality of life assessed using EuroQol EQ-5D at baseline, 30 days post-operatively, 12 and 24 months post-randomisation.
Pain assessed using a 100 point visual analogue scale at baseline, 30 days postoperatively, 12 and 24 months post-randomisation.
Costs per hernia clinically detected at 2 years post-randomisation.
Two-year and long-term costs per additional quality adjusted life (QALY) year gained.

Full Information

First Posted
September 10, 2014
Last Updated
October 10, 2018
Sponsor
University of Birmingham
Collaborators
LifeCell
search

1. Study Identification

Unique Protocol Identification Number
NCT02238964
Brief Title
Reinforcement of Closure of Stoma Site
Acronym
ROCSS
Official Title
A Randomised Controlled Trial of Reinforcement of Closure of Stoma Site Using a Biological Mesh.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
November 2012 (Actual)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
May 18, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Birmingham
Collaborators
LifeCell

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
ROCSS is a randomised controlled trial of the placement of a biological mesh at the site of stoma closure. Our hypothesis is that reinforcing the stoma closure site with a collagen mesh (Strattice®) is superior to the standard technique in preventing herniation at 2 years.
Detailed Description
Closure of complex and contaminated abdominal wounds is challenging and carries risks, including wound dehiscence and incisional hernias. Use of biological meshes in these situations may provide a safe method of reducing these complications, especially long-term incisional hernias. ROCSS will use stoma site closure as a model for biological mesh placement during any difficult contaminated abdominal wall closures. Hernia at the site of stoma closure occurs in up to 30% of patients and is associated with adverse effects on quality of life. In up to 10% of cases, patients are submitted to complex re-operation which carries significant morbidity. Not all patients will report symptoms or undergo repair, as they do not wish to have a further major operation. Incisional hernias at the site of stomas closure form an important and well defined subgroup. If there is a measurable benefit from mesh insertion, elective use of a collagen mesh would warrant consideration in the closure of other difficult, contaminated abdominal wounds. This study will also provide useful information on the value of using a CT scan as an early diagnostic tool of herniation, which could then be used in future abdominal wall studies as a surrogate endpoint for clinical hernia. ROCSS aims to assess whether a biological mesh (collagen tissue matrix) reduces the incidence of clinically detectable stoma closure site hernias at two years compared to standard closure techniques. The primary outcome is Occurrence of clinically detectable hernias at two years post randomisation. Other outcomes include surgical re-intervention rate, surgical complications at 30 days post-operation and 1 year post-randomisation, quality of life and post-operative pain, cost-benefit analysis and radiological hernia rate at one year post-randomisation (an exploratory analysis will compare radiological hernia rate at 1 year with clinical hernia rate at 2 years to assess the value of using a CT scan as an early diagnostic tool of incisional hernias). Randomisation is 1:1 between Strattice® mesh vs. standard closure. The sample size for the trial is 560 (80% power, 10% dropout/crossover, 40% proportional reduction - 25% to 15%) and recruitment will be over 2 years from at least 30 centres. ROCSS will be a double blind (observer blind) randomised controlled trial with a CT scan at one year and clinical follow up at 2 years. Cost benefit analysis and quality of life analysis will be performed at 2 years. The sample size will be reviewed prior to reaching target and may be increased 790 (90% power, 20% dropout/crossover, 40% proportional reduction - 25% to 15%).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hernia

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
790 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Strattice™ Reconstructive Tissue Matrix
Arm Type
Active Comparator
Arm Description
Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
Arm Title
Standard closure
Arm Type
Active Comparator
Arm Description
Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures. Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon.
Intervention Type
Device
Intervention Name(s)
Strattice™ Reconstructive Tissue Matrix
Intervention Description
The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
Intervention Type
Procedure
Intervention Name(s)
Standard Closure
Intervention Description
The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
Primary Outcome Measure Information:
Title
Rate of clinically detectable hernias at two years post-randomisation.
Time Frame
Two years post-randomisation.
Secondary Outcome Measure Information:
Title
Radiological hernia rate at one year post-randomisation.
Description
An exploratory analysis will also compare radiological hernia rate at 1 year with clinical hernia rate at 2 years to assess the value of using a CT scan as an early diagnostic tool of incisional hernias.
Time Frame
One year post-randomisation.
Title
Incidence of developing a symptomatic hernia evaluated at 12 and 24 months postrandomisation.
Description
The clinical detection of hernias defined by palpable fascial defects, and global weaknesses around closed stoma sites without palpable fascial defects, will be recorded. Patient-reported hernia symptoms including a local lump or pain at the site of the stoma closure will also be collected.
Time Frame
One and two years post-randomisation.
Title
Surgical re-intervention rates at 2 years post-randomisation.
Time Frame
Two years post-randomisation.
Title
Surgical complications, including wound infections and seroma formation, at 30 days postoperatively and at 1 year post-randomisation.
Time Frame
30 days postoperatively, 1 year post randomisation
Title
Quality of life assessed using EuroQol EQ-5D at baseline, 30 days post-operatively, 12 and 24 months post-randomisation.
Time Frame
Baseline, 30 days post-operatively, one and two years post-randomisation
Title
Pain assessed using a 100 point visual analogue scale at baseline, 30 days postoperatively, 12 and 24 months post-randomisation.
Time Frame
Baseline, 30 days post-operatively, one and two years post-randomisation
Title
Costs per hernia clinically detected at 2 years post-randomisation.
Time Frame
Two years post-randomisation.
Title
Two-year and long-term costs per additional quality adjusted life (QALY) year gained.
Time Frame
Two-year post-randomisation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Require an elective closure of an ileostomy or a colostomy. Able and willing to provide written informed consent. Aged 18 years or over. Exclusion Criteria: Taking part in another clinical study which is related to the surgical procedure. Allergic to any porcine or collagen products. History of familial adenomatous polyposis, due to increased risk of desmoid tumours. The surgeon determines that a mesh repair will definitely be required e.g. due to large parastomal hernia. Unable or unwilling to provide written informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dion G Morton, MD
Organizational Affiliation
Professor of Colorectal Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hvidovre Hospital
City
Copenhagen
Country
Denmark
Facility Name
Academisch Medisch Centrum
City
Amsterdam
Country
Netherlands
Facility Name
Tameside General Hospital
City
Ashton-under-Lyne
Country
United Kingdom
Facility Name
Royal United Hospital Bath
City
Bath
Country
United Kingdom
Facility Name
Heart of England NHS Foundation Trust
City
Birmingham
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital
City
Birmingham
Country
United Kingdom
Facility Name
Sandwell General Hospital
City
Birmingham
Country
United Kingdom
Facility Name
Pilgrim Hospital
City
Boston
Country
United Kingdom
Facility Name
Bristol Royal Infirmary
City
Bristol
Country
United Kingdom
Facility Name
Broomfield Hospital
City
Chelmsford
Country
United Kingdom
Facility Name
St Peters Hospital
City
Chertsey
Country
United Kingdom
Facility Name
Chesterfield Royal Hospital
City
Chesterfield
Country
United Kingdom
Facility Name
Western Sussex Hospitals NHS Foundation Trust
City
Chichester
Country
United Kingdom
Facility Name
University Hospital Coventry
City
Coventry
Country
United Kingdom
Facility Name
Doncaster Royal Infirmary
City
Doncaster
Country
United Kingdom
Facility Name
Dorset Country Hospital
City
Dorchester
Country
United Kingdom
Facility Name
James Paget University Hospital
City
Great Yarmouth
Country
United Kingdom
Facility Name
St Marks Hospital
City
Harrow
Country
United Kingdom
Facility Name
Raigmore Hospital
City
Inverness
Country
United Kingdom
Facility Name
University Hospitals of Leicester NHS Trust
City
Leicester
Country
United Kingdom
Facility Name
Macclesfield District General Hospital
City
Macclesfield
Country
United Kingdom
Facility Name
Queen Elizabeth the Queen Mother Hospital
City
Margate
Country
United Kingdom
Facility Name
Norfolk & Norwich University Hospital
City
Norwich
Country
United Kingdom
Facility Name
Queens Medical Centre
City
Nottingham
Country
United Kingdom
Facility Name
Salisbury District Hospital
City
Salisbury
Country
United Kingdom
Facility Name
University Hospital of North Tees
City
Stockton-on-Tees
Country
United Kingdom
Facility Name
Royal Stoke University Hospital
City
Stoke-on-Trent
Country
United Kingdom
Facility Name
Kings Mill Hospital
City
Sutton in Ashfield
Country
United Kingdom
Facility Name
Manor Hospital
City
Walsall
Country
United Kingdom
Facility Name
Royal Albert Edward Infirmary
City
Wigan
Country
United Kingdom
Facility Name
New Cross Hosptial
City
Wolverhampton
Country
United Kingdom
Facility Name
Worcestershire Royal Hospital
City
Worcester
Country
United Kingdom
Facility Name
Wythenshawe Hosptial
City
Wythenshawe
Country
United Kingdom
Facility Name
Yeovil District Hospital
City
Yeovil
Country
United Kingdom
Facility Name
York Hospital
City
York
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
32035551
Citation
Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and West Midlands Research Collaborative. Prophylactic biological mesh reinforcement versus standard closure of stoma site (ROCSS): a multicentre, randomised controlled trial. Lancet. 2020 Feb 8;395(10222):417-426. doi: 10.1016/S0140-6736(19)32637-6.
Results Reference
derived
PubMed Identifier
26924621
Citation
Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and the West Midlands Research Collaborative. Feasibility study from a randomized controlled trial of standard closure of a stoma site vs biological mesh reinforcement. Colorectal Dis. 2016 Sep;18(9):889-96. doi: 10.1111/codi.13310.
Results Reference
derived
Links:
URL
http://www.birmingham.ac.uk/ROCSS
Description
Trial website

Learn more about this trial

Reinforcement of Closure of Stoma Site

We'll reach out to this number within 24 hrs